Aetna Autism Spectrum Disorders Coverage

Coverage Criteria

Initial Evaluation and Diagnostic Testing

Covered when ALL of the following are met:

ASD evaluation medical necessity

Included assessment components: ASD-specific developmental evaluation; cognitive and adaptive behavior evaluations; speech, language and comprehensive communication evaluation by a speech-language pathologist; formal audiological hearing evaluation including frequency-specific brainstem auditory evoked response or otoacoustic emissions; medical evaluation including neurologic exam; parent/child interview; quantitative plasma amino acid assays for PKU; selective metabolic testing when clinical features suggest metabolic disorder; genetic testing (karyotype, fragile X) when indicated; comparative genomic hybridization (CGH) when CPB 0787 criteria met; EEG for clinical spells suggesting seizures; PT/OT evaluations for sensorimotor deficits; sleep-deprived EEG when indicated (clinical seizures, suspicion of subclinical seizures, or developmental regression); video-EEG when CPB 0322 criteria met; pharmacotherapy for comorbidities; behavior modification for behavioral comorbidities; intensive educational interventions where documented and appropriate.
See policy for documentation and plan-specific exclusions (educational services may be excluded by some plans).

Selective Metabolic Testing Criteria

Selective metabolic testing is covered when ANY of the following clinical features are present:

Metabolic testing triggers: Cyclic vomiting, recurrent vomiting and dehydration; early seizure; lethargy; hearing impairment; hypotonia; visual impairment; unusual odor; dysmorphic or coarse features; evidence of intellectual disability or inability to rule out intellectual disability; occurrence or adequacy of newborn screening for a birth defect is questionable.

Per AAN/Aetna guidance: perform selective metabolic testing only when these clinical indicators are present.

Experimental and Investigational — Assessment and Treatments

The following assessment tools and treatments are considered experimental and investigational (not covered):

Experimental assessments: All listed tests such as allergy testing (including food allergy for gluten/casein), artificial intelligence–based diagnostic devices (eg, Canvas Dx), metabolomic blood tests (eg, NeuroPointDX NPDX ASD panels), EarliPoint eye-tracking, measurements of plasma oxytocin/vasopressin, salivary RNA assays (Clarifi), whole-exome sequencing for routine ASD diagnosis, magnetoencephalography, plasma central carbon metabolite panels, urinary oligosaccharide testing, hair analysis, intestinal permeability studies, micronutrient panels, stool analysis, and other biomarker/omic panels enumerated in the policy.

See policy lists for full enumeration; these assessments lack established clinical utility for routine ASD diagnosis or management.

Experimental treatments: Treatments considered experimental include acupuncture, antifungal/antiviral therapies for ASD, auditory integration training (AIT)/Tomatis sound therapies, BioMat, chelation therapy, facilitated communication, hyperbaric oxygen therapy (systemic HBOT not established for routine use), stem cell transplantation, neurofeedback/EEG biofeedback, methyl B12, memantine, music therapy, nutritional supplements and exclusion diets (eg, gluten-free/casein-free), immune globulin infusions, prebiotic/probiotic therapies, transcranial direct current stimulation, vestibular stimulation, vision therapy, and other complementary/alternative interventions listed in the policy.

These are classified as experimental/investigational due to insufficient peer-reviewed evidence to support routine coverage.

Conditional diagnostic testing and procedures

Testing and procedures coverage is conditional based on clinical indications:

Selective genetic testing (karyotype, fragile X): Recommended when the child has intellectual disability (or intellectual disability cannot be ruled out), family history of fragile X or undiagnosed intellectual disability, or dysmorphic features.

Per AAN and policy references; consider genetic counseling as appropriate.

Selective metabolic testing: Recommended if the child exhibits lethargy, cyclic vomiting, early seizure, dysmorphic/coarse features, evidence of intellectual disability, inability to rule out intellectual disability, or questionable newborn screening.

Perform selective metabolic testing only when clinical features suggest metabolic disorder.

EEG and neuroimaging: Routine neuroimaging (CT, MRI, PET, SPECT, fMRI) is not supported for routine ASD evaluation; perform EEG only for clinical seizures, high suspicion of subclinical seizures, or history of regression. Sleep-deprived EEG and video-EEG are indicated when specific clinical criteria are met.

AAN guidance: imaging and EEG are conditional, not routine.

Core supportive therapies (education, speech, OT/PT, AAC)

Covered when supported by guideline-recommended evidence and individualized goals

Core recommended services: Educational services beginning as soon as ASD is suspected with intensive, developmentally appropriate programming; speech/language therapy, occupational therapy, and physical therapy when clinically indicated; and augmentative/alternative communication (AAC) when functional speech is absent or limited.minimum 25 hours/week recommended by NAS as an example for intensive educational programming

Document individualized goals, intensity, duration and measurable objectives; check plan exclusions because some plans exclude educational services or AAC devices.

Intensive behavioral interventions (ABA/EIBI, Lovaas)

Covered only with strong evidence of benefit or within research/exceptional-case review

Intensive behavioral interventions and ABA/EIBI: Applied behavior analysis (ABA) and early intensive behavioral interventions (EIBI/Lovaas-type programs) have mixed, methodologically limited evidence; coverage is conditional on documented medical necessity, program specifics (goals, intensity, duration), measurable objectives, and review (prior authorization or research protocol) as appropriate.intensity and duration associations with outcomes are unestablished

Multiple systematic reviews and technology assessments report inconsistent results and call for higher-quality trials; many plans may require documentation and prior authorization.

Experimental/insufficient-evidence therapies

Not routinely covered / considered experimental or unproven

Unproven or not supported therapies: Hair analysis, secretin infusion, facilitated communication, immune globulin infusions, sensory integration therapy, vision therapy, auditory integration training (AIT)/Tomatis sound therapy, gluten/casein elimination diets, chelation therapy, BioMat, topical hyperbaric devices, many nutritional supplements and other modalities enumerated in the policy — evidence insufficient or not supportive for routine effectiveness in treating core ASD symptoms.evidence classified as insufficient/experimental by guideline assessments

Several RCTs and systematic reviews found no benefit for some modalities (eg, secretin, AIT); these are considered not medically necessary or investigational.

Auditory Integration and Tomatis therapy — Not supported by evidence

Sound therapies (AIT/Tomatis)

Sound therapies (AIT/Tomatis): Systematic reviews and Cochrane analyses identified multiple small RCTs (total n~182) with heterogeneous methods and outcomes and concluded there is no evidence that auditory integration training (AIT) or other sound therapies are effective treatments for ASD.

Given lack of demonstrated benefit, AIT/Tomatis are not supported for routine coverage.

Hyperbaric oxygen — limited positive trial but insufficient consensus

Hyperbaric oxygen therapy

HBOT trial findings: A multicenter randomized double-blind controlled trial (n=62) using 40 hourly sessions at 1.3 atm with 24% oxygen reported short-term improvements on several clinician- and parent-rated scales (CGI, ABC, ATEC), but professional hyperbaric medicine societies do not approve autism as an indication and additional trials are needed to confirm durability and optimal parameters.40 sessions; 1.3 atm; 24% O2

Evidence insufficient to endorse routine coverage; prior authorization recommended when used in exceptional circumstances with robust documentation.

Massage — limited/low-quality evidence

Massage therapy

Massage: Systematic reviews identified a small number of controlled studies (6) with high risk of bias; while some small RCTs reported benefits for language, sensory profile or social communication, overall evidence is limited and not definitive.

Larger rigorous RCTs needed; routine coverage not established.

Omega-3 supplements — Not supported by current RCTs

Omega-3 fatty acid supplementation

Omega-3: Randomized trials (total n small across trials) found no evidence that omega-3 supplements affect social interaction, communication, stereotypy, or hyperactivity in ASD; current RCT data do not support use for core ASD symptoms.

Insufficient evidence to support routine coverage for core symptom improvement.

Neurofeedback — preliminary clinic-based evidence

Neurofeedback (NFB)

Neurofeedback: Clinical series and nonrandomized clinic data report improvements in attention and other measures with programs typically including 40–60 sessions; evidence is preliminary and primarily uncontrolled or observational.40-60 sessions

Considered investigational for core ASD symptom treatment pending controlled trial data.

Chiropractic — insufficient evidence

Chiropractic care

Chiropractic: Systematic review identified case reports, cohort studies and one randomized comparison with insufficient evidence to support chiropractic care for ASD; further definitive studies are encouraged.

Insufficient evidence for routine coverage.

Hippotherapy — preliminary positive reports

Hippotherapy/equine-assisted activities

Equine-assisted activities: Small nonrandomized studies report reductions in autism symptom severity and improved parent-child interaction measures over 3–6 months; these preliminary findings require validation in well-designed studies before routine coverage is recommended.3-6 months typical interventions

Not established as standard therapy in major reviews; consider investigational.

Pharmacologic evidence summary

SSRIs and investigational agents: Cochrane and systematic reviews found no evidence of benefit of SSRIs in children and emerging evidence of harm; some agents (eg, arbaclofen, arbaclofen-like compounds) have preliminary open-label signals but require placebo-controlled trials; risperidone and aripiprazole are FDA-approved for irritability associated with autistic disorder and supported for that indication.

Use pharmacotherapy according to established psychiatric indications and monitoring; check FDA labeling and prior authorization rules for antipsychotics in pediatric patients.

Acupuncture — mixed evidence, methodological concerns (including scalp acupuncture)

Acupuncture and scalp acupuncture

Acupuncture: Systematic reviews/meta-analyses report reductions in some rating scales (CARS, ABC) when acupuncture is used adjunctively, but heterogeneity of methods and quality limitations limit conclusions about clinical effectiveness.

High-quality RCTs needed before broad application.

Scalp acupuncture (SAT): Meta-analyses of SAT trials report improvements on CARS, ABC and PEP-3 in some studies, but methodological heterogeneity and risk of bias warrant further high-quality trials before routine use.

Promising but not definitive evidence.

Evidence summaries (no explicit coverage rules)

Evidence summaries and implications

Scalp acupuncture: Systematic reviews report possible benefit of SAT in some trials but heterogeneity and quality concerns require larger high-quality RCTs before acceptance.

See acupuncture evidence summaries for details.

Auditory Integration Training: Multiple systematic reviews (NAS, Cochrane) conclude there is no evidence that AIT or other sound therapies are effective for ASD; studies are small and heterogeneous.

AIT is considered not medically necessary.

Electroconvulsive therapy (ECT): Case reports/series suggest possible benefit for autistic catatonia but evidence is limited and controlled trials are needed; use is exceptional and requires careful documentation.

Considered only in specific clinical contexts with specialist involvement.

Not established / Investigational — coverage stance based on summarized evidence

Coverage stance based on summarized evidence in these sections

Investigational or not routinely covered interventions: Music therapy (IMT), nutritional exclusion diets (eg, GFCF), intranasal oxytocin for social deficits, prebiotic/probiotic therapy for core ASD symptoms, saliva-based biomarker tests (eg, Clarifi), and certain metabolomic panels are considered investigational or not established for routine coverage due to inconsistent, preliminary, or insufficient evidence of benefit for core ASD symptoms.

Use in research settings or exceptional-case review only; prior authorization and documentation may be required if considered.

Biomarker tests — conditional / investigational

Diagnostic adjunct tests

Salivary RNA classifier: Salivary poly-omic RNA measurement (eg, Clarifi) has shown promising AUC (~0.88) in validation cohorts and could improve referral specificity, but requires broader external validation and assessment of confounders before routine clinical adoption as a diagnostic test.

Considered investigational/conditional pending further validation across diverse populations and assessment of test limitations.

Many Aetna plans exclude coverage of services that are primarily educational in nature (for example, speech therapy or ABA services provided during class). Providers must check the member's benefit plan for applicable exclusions before billing medical benefits for developmental or educational services. In the context of developmental testing and ASD evaluation, multidisciplinary assessments (developmental, cognitive, speech/language, audiology, medical) remain part of the medically necessary diagnostic workup when performed by qualified certified/licensed health care professionals, but services that are delivered as educational interventions in school settings may be excluded under some plans and risk denial if billed to medical benefits.

The policy lists numerous procedures and tests that lack adequate peer-reviewed evidence to support their routine use in assessment or management of ASD. Examples specifically noted include allergy testing (including food allergy testing for gluten/casein) and erythrocyte glutathione peroxidase studies. These and other listed investigations are considered experimental/investigational because available literature does not establish clinical utility for ASD management.

The policy identifies specific HCPCS/CPT items that are questioned or not covered for the indications described. Examples include A4575 (topical hyperbaric oxygen chamber), A9152 (single vitamin/mineral per dose — e.g., omega-3 supplements), and E0446 (topical oxygen delivery system). These codes are among those explicitly listed in the code section as not supported for routine ASD-related indications.

A range of diagnostic and laboratory tests and biomarker panels are listed as unsupported for routine ASD evaluation or management. Examples include hair analysis for trace elements, intestinal permeability studies, stool analysis, measurement of urine oligosaccharides, and broad panels of immunologic/neurochemical or micronutrient testing. The AAN and other reviews cited in the policy found inadequate evidence to support these tests for ASD care.

Although a multicenter randomized trial of hyperbaric oxygen reported short-term improvements with a regimen of 40 hourly sessions at 1.3 atm with 24% oxygen, the policy notes that professional hyperbaric medicine organizations (Undersea Hyperbaric Medical Society and European Committee for Hyperbaric Medicine) do not approve autism as an indication for HBOT. Additional studies are required to establish reproducible benefit and clinical consensus.

Auditory Integration Training (AIT), Tomatis sound therapy and similar sound‑based interventions lack consistent evidence of effectiveness. Systematic reviews and Cochrane analyses identified small, heterogeneous trials (totaling 182 participants across AIT/Tomatis studies) and concluded there is no evidence that AIT or other sound therapies are effective as treatments for ASD; these therapies are therefore considered unsupported.

Routine testing for common gene polymorphisms (for example, MTHFR 677C>T and 1298A>C) is not recommended as non‑specific population screening. The policy cites limited, conflicting data and concludes there are very limited clinical indications for such polymorphism testing in ASD evaluation.

Metabolomic blood tests such as the first‑generation NeuroPointDX (NPDX ASD Test) are described in the policy as investigational. While CAMP/NeuroPointDX identified metabolic 'metabotypes' in subsets of ASD subjects, the policy states that the clinical utility of metabolomic testing for diagnosing or managing ASD has not been established and routine use is not supported.

Nutritional interventions evaluated in the literature — including gluten‑free/casein‑free (GFCF) diets and probiotic supplementation — have produced inconsistent and limited results. Systematic reviews and randomized trials summarized in the policy conclude there is no proven efficacy of GFCF diets and that probiotic/prebiotic evidence is preliminary; these approaches are not supported as established therapies for core ASD symptoms.

UpToDate reviews cited in the policy do not mention saliva‑based analysis testing as a validated screening or diagnostic tool for ASD. The policy specifically notes that tests for yeast metabolites, gut permeability, and micronutrient assays are not indicated due to lack of empirical data, and saliva analysis is not endorsed as part of routine ASD evaluation.

Measurement of urine oligosaccharides is not described in UpToDate reviews as a management or diagnostic tool for ASD. The policy therefore does not support routine urine oligosaccharide measurement as part of ASD evaluation.

Eye‑tracking index tests reported in research were performed under controlled laboratory conditions or using prototype devices, and authors caution that multi‑site reproducibility and real‑world implementation have not been established. The policy notes limited applicability of these eye‑tracking methods to routine clinical practice until broader validation and standardized implementation are available.

The policy classifies a long list of tests and treatments as experimental and investigational and therefore not medically necessary due to insufficient peer‑reviewed evidence. This includes assessment tools (e.g., certain biomarker panels, unvalidated genetic panels, prototype AI devices, eye‑tracking panels) and therapies (e.g., chelation, stem cell transplantation, many supplements, systemic HBOT pending confirmatory evidence). Providers should regard listed items as investigational unless future high‑quality evidence demonstrates clinical benefit.

Routine neuroimaging (CT, MRI, PET, SPECT, fMRI) and routine EEG are not supported in the absence of clinical indications. The AAN and other reviews cited in the policy recommend neuroimaging only for selected clinical scenarios; EEG is indicated when clinical seizures, subclinical seizure suspicion, or regression are present. Hair analysis, intestinal permeability testing and a variety of other laboratory investigations are similarly listed as unsupported for routine ASD evaluation.

Secretin and Tomatis sound therapy have been examined in randomized controlled trials and systematic reviews; well‑designed trials did not demonstrate treatment‑related benefit for secretin, and Tomatis trials failed to show language‑specific effects over placebo. Consequently, these specific sound‑based therapies are considered not medically necessary for autism treatment.

Auditory integration training and similar sound therapies are not supported by the evidence base. Systematic reviews, including Cochrane analyses, concluded there is no evidence that AIT or other sound therapies are effective for ASD, and therefore these interventions are not medically necessary.

High‑quality randomized trials summarized in Cochrane reviews found no evidence that omega‑3 fatty acid supplementation improves core ASD symptoms (social interaction, communication, stereotypies, hyperactivity). The policy therefore does not support routine omega‑3 supplementation for core ASD symptom reduction.

Across systematic reviews and randomized trials, there is no convincing evidence that auditory integration therapy, Tomatis therapy, or other sound‑based interventions are effective treatments for autism. The policy states that AIT and related sound therapies lack evidence of efficacy and are not supported as treatments.

The policy notes that genetic testing for polymorphisms or candidate genes (for example, DRD2, HTR2C, MTHFR, RELN, SLC25A12, UGT2B15) lacks demonstrated clinical utility and cost‑effectiveness for routine ASD evaluation. Available association studies are inconsistent, and economic analyses for these tests are lacking; such testing is therefore not established as medically necessary for general screening or diagnosis.

A high‑quality, multicenter randomized trial of improvisational music therapy (IMT) added to enhanced standard care did not show significant benefit on the ADOS social affect domain over 5 months. Based on that evidence, IMT is not supported as an evidence‑based treatment for core ASD symptom reduction in routine practice.

Systematic reviews and randomized trials evaluating nutritional approaches found no proven efficacy for gluten‑free/casein‑free (GFCF) diets, and probiotic/prebiotic interventions have produced mixed, preliminary results. The policy does not recommend these diets or supplements as evidence‑based treatments for core ASD symptoms.

A large, 24‑week, phase II randomized trial of daily intranasal oxytocin in children and adolescents with ASD showed no significant improvement versus placebo on the primary social‑withdrawal outcome. The policy concludes that routine intranasal oxytocin use for social deficits in ASD is not supported by current randomized trial evidence.

The policy explicitly states that there is no evidence to support routine use of saliva analysis testing, assays for yeast metabolites, gut permeability testing, or broad micronutrient screening for evaluation or diagnosis of ASD. These modalities are not mentioned as validated management tools in UpToDate reviews cited by the policy and are therefore not supported.

The policy enumerates additional tests and treatments that lack guideline‑level evidence, including routine measurement of citrate synthase enzyme activity and urine oligosaccharide measurement, and notes that methyl B12 has limited and inconsistent trial data. These items are considered investigational or not established for routine ASD management.

Machine‑learning based eye‑tracking approaches show promise in research settings but the policy highlights important limitations: heterogeneity of methods, small sample sizes, lack of standardized implementation, limited external validation, and inconsistent reporting of validation/test sets. Because of these issues, ML‑based eye‑tracking currently has limited clinical utility and remains investigational pending robust, transparent validation.

Provider Actions & Administrative Requirements

Prior Authorization

Some Codes Require Prior Authorization

Some CPT/HCPCS codes referenced in this policy may require prior authorization under plan-specific rules. Providers should verify prior authorization requirements with the member's benefit plan before scheduling services to avoid claim denials or delays.

Verify plan-specific prior authorization requirements for selected CPT/HCPCS codes listed in this policy.
Confirm prior authorization when billing for intensive programs, device procurements, or high-cost services.

Prior Authorization

Device / Service Prior Authorization and Coverage Linkage

Coverage for devices and linked services (for example AAC devices and associated evaluation/therapy) may be contingent on prior authorization and demonstration of medical necessity. Ensure device prescriptions are tied to documented functional needs and an individualized plan of care that shows linkage between the device and covered therapeutic services.

Obtain prior authorization when the plan requires it for augmentative and alternative communication (AAC) devices (e.g., E1902, E2500–E2599) and document functional benefit.
Include device-specific justification and the relationship to concurrent therapy (speech/OT) in the prior auth submission.

Prior Authorization

Prior Authorization for Intensive Behavioral Programs

Intensive behavioral intervention programs (e.g., extended-hour ABA/Lovaas-type programs, 0362T/0373T) may require prior authorization given limited or inconsistent evidence and high resource use. Provide detailed documentation of program content, intensity, duration, qualified personnel, and individualized goals when requesting coverage.

Document program model, weekly hours, setting, staff qualifications, and measurable individualized functional goals.
Expect prior authorization review for high-intensity or long-duration behavioral programs; submit progress measurement plans and planned reassessment intervals.

Prior Authorization

Hyperbaric Oxygen — Prior Authorization Suggested

Hyperbaric oxygen therapy (e.g., G0277, 99183) has mixed evidence for ASD. Prior authorization is suggested when hyperbaric oxygen is being requested for autism to ensure appropriateness and to capture required treatment parameters and trial justification.

Provide clinical rationale referencing trial parameters (e.g., 1.3 atm, 24% oxygen, 40 sessions) when submitting prior authorization requests.
Document age, baseline severity, prior therapies tried, number of sessions requested, pressure and oxygen concentration, and planned outcome measures.

Prior Authorization

Intranasal Oxytocin — Prior Authorization Consideration

Intranasal oxytocin has not demonstrated meaningful benefit in large randomized trials. Consider prior authorization or medical-review processes for requests to use intranasal oxytocin for ASD to document rationale and prior treatment trials.

Document the clinical justification, prior pharmacologic treatments tried and failed, and target symptoms when seeking coverage for intranasal oxytocin.
Be prepared for coverage denial where evidence does not support clinical benefit.

Documentation Required

Genetic Testing (CMA/WES) — Clinical Context and Documentation

Genetic testing such as chromosomal microarray analysis (CMA) and whole-exome sequencing (WES) should be ordered with clear clinical context. Prior authorization may be required and orders should document specific indications that meet medical necessity criteria.

Provide phenotypic detail (dysmorphology, developmental regression, intellectual disability, family history) supporting CMA/WES.
Reference applicable genetic testing policy criteria (e.g., CPB 0787) and include previous testing results when available.

Documentation Required

AI-based Device Reporting and Follow-up

When AI-based diagnostic devices (e.g., multi-input software producing ASD-positive/negative/indeterminate outputs) are used, report results with clarity and ensure follow-up plans. Indeterminate or discordant outputs should trigger further evaluation or specialist referral.

Include Device output (positive/negative/indeterminate), inputs used (questionnaire, video, HCP assessment), and how the result was reconciled with clinical examination in the medical record.
If the Device yields an indeterminate result or conflicts with clinical judgment, document referral to a neurodevelopmental specialist and planned next steps.

Note

Prior Authorization — None Specified in Policy Excerpts

No universal prior authorization rules are specified in these excerpts. Providers must consult the member's specific plan documents and prior authorization portals for applicable requirements.

Contact plan administrator or use payer prior authorization system to confirm whether a service requires prior authorization.
Maintain documentation of prior auth approvals in the medical record to support claims.

Prior Authorization

Prior Authorization Guidance

General prior authorization guidance: submit a clear clinical rationale, relevant prior treatment history, objective baseline measures, proposed treatment plan (including duration/intensity), and measurable outcome metrics to support medical necessity reviews.

Attach supporting clinical notes, standardized assessment results, and prior treatment documentation with the authorization request.
For device requests, include supplier information, device model, and expected functional improvements.

Denial Risk

Evidence Limitations Risking Denial

Interventions with limited, inconsistent, or low-quality evidence (e.g., certain intensive behavioral programs, some complementary therapies) carry a higher risk of denial. Ensure documentation justifies medical necessity and includes measurable goals and progress tracking.

Anticipate denials when peer-reviewed literature does not support clinical benefit; include detailed justification and objective outcome measures when requesting coverage.
Examples of high denial-risk interventions include sound therapy (AIT/Tomatis), some complementary/alternative treatments, and tests without established clinical utility.

Denial Risk

Unestablished Clinical Utility — Metabolomic Testing

Metabolomic testing (e.g., NeuroPointDX / CAMP-derived panels) currently lacks established clinical utility for diagnosing or managing ASD. Prior authorization is reasonable and test orders should document how results would change management.

Document specific intended use (screening vs. diagnostic stratification) and how positive/negative results would alter clinical care.
Be prepared for medical-review denial where the clinical utility for management has not been established.

Note

Not Applicable — Bibliography / Administrative Note

This section contains bibliographic material and provider-action guidance; it is not a benefits contract. Providers remain responsible for confirming coverage under the member's plan.

Clinical Policy Bulletins do not substitute for plan documents; consult benefit descriptions for coverage and exclusion details.
Retain copies of relevant citations when submitting prior authorization requests.

Documentation Required

Indeterminate Device Outputs Trigger Further Evaluation

If an AI Device returns an indeterminate or uncertain output, document that the result prompted additional assessment and specialist referral. Indeterminate outputs often indicate complex or atypical presentations requiring expert evaluation.

Record the reason for indeterminate output (insufficient inputs, complex presentation) and the plan for specialist follow-up.
Track outcomes of subsequent specialist assessments and include them in the member's record.

Documentation Required

Qualified Provider and Indication

Qualified providers: evaluations and interventions should be performed by appropriately certified/licensed professionals (e.g., developmental pediatrician, child neurologist, child psychiatrist, licensed psychologist, speech-language pathologist) and documented with relevant credentials and scope of practice.

Ensure the ordering and performing clinician's credentials and specialty are included in authorization requests and visit documentation.
For procedures requiring specialized personnel (e.g., behavioral programs with on-site supervising clinician), document staff roles and qualifications.

Documentation Required

Documentation Expectations for Supportive Therapies

For supportive therapies (speech, occupational, physical, AAC training), document individualized goals, baseline functional status, frequency and duration of therapy, progress notes with objective measures, and plan for reassessment to support ongoing coverage.

Include specific functional goals (e.g., expressive language milestones, ADL improvements), measurable progress indicators, and caregiver training provided.
Link therapy goals to the member's overall treatment plan and educational/behavioral objectives.

Documentation Required

Hyperbaric Oxygen — Documentation Expectations

Hyperbaric oxygen documentation: when used for ASD, include patient age, baseline severity, atmospheric pressure, oxygen concentration, number of sessions, adverse events, and objective outcome measures to justify the trial and any continuation.

Record treatment parameters (e.g., 1.3 atm, 24% O2, 40 sessions) and standardized outcome instruments used to measure response.
Document safety monitoring and any side effects during the course of therapy.

Documentation Required

Memantine — Clinical Documentation

Memantine has mixed/negative evidence for core ASD symptoms. When memantine is prescribed, document the clinical rationale, target symptoms, prior therapies tried, trial duration, dosing, and objective outcome assessments to support medical necessity.

Note prior treatments and why memantine is being considered (e.g., adjunct for specific symptoms).
Capture baseline standardized measures and pre-specified endpoints for evaluation of effectiveness.

Documentation Required

Saliva Test Intended Use and Documentation

Saliva-based tests (e.g., Clarifi) are intended for children 18 months through 6 years with clinical suspicion of ASD (for example, positive M-CHAT-R). Document the indication and be aware of conditions that may invalidate results.

State the clinical suspicion (screening result or clinical concerns) and the child's age on the test order.
Be aware of limitations/invalidating conditions (dental caries, fever, feeding tubes, known chromosomal anomalies, epilepsy, recent head trauma) and document their absence or presence.

Documentation Required

Documentation for Genetic Testing

Genetic testing orders should include detailed clinical indications: developmental history, family history, dysmorphic features, regression, and prior newborn screening status. Provide prior testing results and phenotypic stratification when available.

When ordering CMA/WES, include morphology scores or descriptions of congenital anomalies and neurodevelopmental phenotype.
Attach prior karyotype, fragile X testing, and newborn screening results if available to streamline review.

Documentation Required

Recommended Supporting Laboratory and Outcome Documentation for Methyl B12 Therapy

When assessing Methyl B12 therapy, include recommended baseline and follow-up laboratory measures (methionine, SAM/SAH ratio, glutathione status), clinical outcome tracking (CGI, ABC, SRS), dosing regimen, and objective assessment intervals.

Document baseline metabolic labs (plasma methionine, SAM, SAH, glutathione) and repeat testing at pre-specified intervals to correlate biochemical changes with clinical response.
Record clinician-rated and caregiver-rated outcome scales and link changes to treatment exposure.

Documentation Required

Definitions

Selective metabolic testing — indications and example clinical features

Indications for selective metabolic testingCovered when any of: cyclic/recurrent vomiting with dehydration, early seizures, lethargy, hypotonia, visual or hearing impairment, unusual odor, dysmorphic or coarse features, evidence of intellectual disability (or cannot be excluded), or questionable newborn screening.

Role in ASD workupSelective metabolic testing is recommended only when clinical/physical findings suggest a metabolic disorder rather than as routine screening.

Examples of clinical features prompting testingCyclic vomiting, early seizure, lethargy, hearing impairment, hypotonia, visual impairment, unusual odor; or dysmorphic/coarse features.

Autism Spectrum Disorders (ASD) — definition

Definition of ASDAutism spectrum disorders (ASD) are biologically based chronic neurodevelopmental disorders characterized by impairments in social communication/interaction and restricted, repetitive behaviors.

Included conditionsASD includes autism, childhood disintegrative disorder, and Asperger’s syndrome; signs typically present before age 3.

Diagnostic emphasisDiagnosis relies on behavioral assessment and multidisciplinary evaluation to make an accurate diagnosis and plan intervention.

Secondary autism — autistic features with other neurologic disorders

Definition of secondary autismAutistic features occurring in association with other neurologic disorders (e.g., tuberous sclerosis, fragile X syndrome, phenylketonuria) are considered secondary autism.

Testing contextGenetic testing (karyotype, fragile X) is recommended when intellectual disability is present or cannot be excluded, or when dysmorphic features or family history suggest an underlying syndrome.

Clinical implicationRecognition of secondary autism guides targeted diagnostic testing and management for the underlying neurologic disorder.

Augmentative and Alternative Communication (AAC) — definition and examples

AAC definitionAugmentative and Alternative Communication (AAC) comprises strategies and devices to compensate for severe expressive communication disorders, including non-speech symbol systems, communication boards, and voice output devices.

Examples of AACSign language, visual symbols (pictures/words) on communication boards, synthesized or digitized speech voice-output devices, and assistive technology adaptations.

Role in ASD programsAAC can be useful for children who do not acquire functional speech or have difficulty processing spoken language and is part of comprehensive educational programming.

Lovaas therapy / EIBI — definition and typical intensity (30–40 hrs/week)

Lovaas / EIBI definitionLovaas therapy (Early Intensive Behavioral Intervention, EIBI) is an intensive early behavioral intervention using discrete trial training and reinforcement to shape social behaviors.

Typical intensityTypically delivered at approximately 30–40 hours per week in original Lovaas-style programs.

Evidence caveatOriginal studies had methodological limitations; overall evidence is mixed and higher-quality trials are needed to define optimal intensity and duration.

Tomatis sound therapy — definition and device description

Tomatis therapy definitionTomatis sound therapy uses progressively filtered classical music delivered via a device called the 'Electronic Ear' to modify auditory input and rehabilitate middle ear muscles and auditory processing.

Device descriptionThe Electronic Ear filters/gates music to create a progressive program intended to 'awaken' the ear and full range of high frequencies.

Trial evidenceRandomized controlled data have not demonstrated language improvement attributable to the Tomatis device in children with autism in the cited trial.

Hyperbaric oxygen therapy (HBOT) — definition and example parameters (1.3 atm, 24% O2)

HBOT definitionHyperbaric oxygen therapy (HBOT) is treatment in which an individual breathes increased oxygen concentrations at greater than normal atmospheric pressure.

Example trial parametersA multicenter RCT used 40 hourly sessions at 1.3 atmospheres (atm) with 24% oxygen (treatment) versus slightly pressurized room air (1.03 atm, 21% O2) as control.

Documentation recommendationDocumentation for HBOT trials should include age, number of sessions (40 described), treatment pressure and oxygen concentration, and measured outcomes (CGI, ABC, ATEC).

SAT — scalp acupuncture treatment definition

SAT definitionScalp acupuncture treatment (SAT) is a form of acupuncture applied to the scalp and has been evaluated in multiple trials for children with ASD.

Evidence summarySystematic reviews/meta-analyses reported improvements on CARS, ABC and PEP-3 in pooled SAT trials but noted heterogeneity and methodological limitations requiring higher-quality RCTs.

Age-stratified outcomesTrials reported separate outcome analyses for children under 3 years and for those above 3 years in meta-analytic summaries.

AIT — Auditory Integration Training definition

AIT definitionAuditory Integration Training (AIT) is a therapy intended to reduce hypersensitivity to sound by using modified auditory stimulation.

Technique descriptionProponents propose music-based 'massage' of the middle ear and cochlea to reduce hyper-sensitivity and improve auditory processing; Tomatis is a related filtered-music approach.

Evidence conclusionSystematic reviews and the NAS/AAP conclude insufficient evidence that AIT or other sound therapies are effective for ASD; Cochrane review found no evidence of benefit.

DIR/Floortime — definition and parent-engagement therapy description

DIR/Floortime definitionDIR/Floortime (Developmental, Individual-differences, Relationship-based) is a parent-engagement therapy focusing on floor-based play to promote social and communicative development.

Session formatFloortime sessions are described as series of 20- to 30-minute periods during which parents interact and play with their child on the floor.

Evidence statusThe evidence base is emerging with studies of varying quality; parental engagement correlates with better child outcomes in some reports, but higher-quality trials are needed.

Polymorphism — definition and example polymorphisms with weak/conflicting association

Polymorphism definitionA polymorphism is a genetic variant that does not necessarily affect gene function; common polymorphisms (e.g., MTHFR 677C>T and 1298A>C) have weak and conflicting associations with ASD and limited clinical indications for testing.

Example polymorphismsMTHFR 677C>T and 1298A>C cited as examples with weak/conflicting associations and not recommended as routine screening in asymptomatic populations.

Clinical implicationTesting for common polymorphisms is generally not indicated as non-specific population screening due to limited clinical relevance.

Metabolomics / metabotype — definition and concept

Metabolomics / metabotype definitionMetabolomics is the large-scale study of small molecules (metabolites) in biofluids; a 'metabotype' describes a metabolic subtype detected in a subset of individuals with ASD.

Clinical test exampleNeuroPointDX (NPDX) ASD Test measures central carbon metabolites to identify metabolic subtypes; clinical utility for routine diagnosis/management is unestablished.

ImplicationMetabolomic profiles may identify subgroups (eg, amino-acid dysregulation metabotypes) but require further validation before informing routine care.

Clarifi ASD saliva test — provider-administered saliva swab assay intended use and age range

Intended useThe Clarifi ASD saliva test is a provider-administered saliva swab assay intended to report a probability of ASD for children with clinical suspicion (eg, positive M-CHAT-R).

Age rangeIndicated for children aged 18 months through 6 years.

Validity considerationsClinical validity may be affected by dental caries, fever, feeding tubes, chromosomal abnormalities, epilepsy, head trauma and requires further validation before routine use.

Morphological severity groups — essential/equivocal/complex phenotypic stratification

Morphological severity groupsPhenotypic stratification used in WES/CMA studies: essential (scores 0-3), equivocal (4-5), and complex (≥6) to compare molecular diagnostic yields.

Diagnostic yield implicationCombined molecular diagnostic yield (CMA + WES) was higher in children with more complex morphological phenotypes compared with essential group.

Use in test selectionMorphologic stratification may inform selection and expected yield of molecular diagnostic testing in ASD evaluations.

Dysbiosis — definition and common taxa changes reported in ASD literature

Dysbiosis definitionDysbiosis refers to alterations in gut microbiota composition reported in ASD, with variable increases/decreases in taxa such as Clostridium, Bacteroides, Bifidobacterium and others.

Reported taxa changesStudies reported higher abundance of genera including Bacteroides, Parabacteroides, Clostridium, Faecalibacterium and Phascolarctobacterium and lower Coprococcus and Bifidobacterium in some ASD cohorts.

Evidence limitsFindings are inconsistent across studies and confounded by diet, antibiotics and GI symptoms; further research needed to determine causal relevance.

NF-κB — definition and relevance to ASD biology

NF-κB definitionNF-κB is a family of transcription factors involved in inflammatory responses and has been implicated in ASD neurobiology based on human and animal studies.

Relevance to ASDSystematic reviews identified studies linking altered NF-κB expression/activation to ASD, supporting investigation as a potential biomarker or therapeutic target.

Research statusEvidence is preliminary and further work is needed to clarify whether NF-κB changes are causal or secondary in ASD pathogenesis.

Eye-tracking index test — definition as automated measure of social visual engagement

Eye-tracking index test definitionAn automated, performance-based tool measuring social visual engagement (eye fixation patterns) used as an objective biomarker to aid early ASD diagnosis in young children.

Study performanceProspective studies in children 16–30 months showed AUROC ~0.89-0.90 with sensitivity ~81% and specificity ~82–90% in discovery and replication cohorts.

LimitationsMost ML/eye-tracking studies are heterogeneous; applicability to routine clinical practice, multi-site reproducibility, and external validation remain investigational.

AI-based device — definition of software/hardware applying ML to physiologic or behavioral data

AI-based device definitionSoftware and/or hardware (including wearables or smartphone-based tools) that applies machine learning algorithms to physiologic or behavioral data to assist diagnosis or triage for ASD.

Use considerationsDevices may produce determinate positive/negative outputs for a subset of children but indeterminate outputs are common and require specialist follow-up; cost, access (smartphone requirement), and external validation are important considerations.

Evidence statusStudies are promising but largely pilot or feasibility in design; broader replication, validation, and assessment of equity and reimbursement implications are needed before routine adoption.

80047	Basic metabolic panel (Calcium, ionized).
80048	Basic metabolic panel (Calcium, total).
80053	Comprehensive metabolic panel.
81228	Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, BAC or oligo-based CGH).
81229	Interrogation of genomic regions for copy number and SNP variants for chromosomal abnormalities.
81349	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-pass sequencing analysis.
83655	Chemistry examination; lead.
92605	Evaluation for prescription of non-speech-generating augmentative and alternative communication device.
96112	Developmental test administration by physician or other qualified health care professional, with interpretation and report.
96113	Same as 96112 (range).

0063U	Neurology (autism), 32 amines by LC-MS/MS — listed under CPT codes not covered for indications in the CPB.
0170U	Neurology (ASD), RNA NGS saliva — listed as not covered/experimental.
0263U	Neurology (ASD), quantitative central carbon metabolites — listed as not covered/experimental.

70544	Magnetic resonance angiography, head; without contrast material(s).
70545	Magnetic resonance angiography, head; with contrast material(s).
70546	Magnetic resonance angiography, head; without contrast material(s), followed by contrast material(s) and further sequences.
70551	Magnetic resonance imaging, brain; without contrast material.
70552	Magnetic resonance imaging, brain; with contrast material(s).
70553	Magnetic resonance imaging, brain; without contrast, followed by contrast and further sequences.
76390	Magnetic resonance spectroscopy.
90870	Electroconvulsive therapy (includes necessary monitoring).
90901	Biofeedback training by any modality [neurofeedback/EEG biofeedback].
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual.

A4575	Topical hyperbaric oxygen chamber, disposable. (listed as not covered for CPB indications)
A9152	Single vitamin/mineral/trace element, oral, per dose, not otherwise specified [omega-3 fatty acid supplements]. (listed as not covered for CPB indications)
E0446	Topical oxygen delivery system, not otherwise specified. (listed as not covered for CPB indications)
G0068	Professional services for the administration of infusion drug(s) in the home; listed among HCPCS not covered for CPB indications.
J2850	Injection, secretin, synthetic, human, 1mcg. (listed among HCPCS)
P2031	Hair analysis (excluding arsenic). (listed among HCPCS)

81291	Methylenetetrahydrofolate Reductase (MTHFR), DNA Mutation.
81415	Exome; sequence analysis.
81416	Sequence analysis, each comparator exome.
81417	Re-evaluation of previously obtained exome sequence.
83090	Homocysteine.
83540	Iron.
83605	Lactate (lactic acid).

OpenPayer

Autism Spectrum Disorders — Coverage Criteria

Coverage Criteria

Coding

Provider Actions & Administrative Requirements

Background

Definitions

Level of Care Criteria

Applied Behavior Analysis / Intensive Educational Intervention Criteria

Treatment Modalities

Visit Limits & Service Intensity

Revision History